Part One: The Nature of Gratuitous Goods

Chapter 3 of Abundance, Generosity, and the State: An Inquiry into Economic Principles audiobook.

From pp. 95–116 in the print edition.

Chapter 3. Motivations of Donations

Part Three: Gratuitous Goods and the State

Chapter 10 of Abundance, Generosity, and the State: An Inquiry into Economic Principles audiobook.

From pp. 291–332 in the print edition.

Chapter 10. The State as a Provider of Gratuitous Goods

Part Three: Gratuitous Goods and the State

Chapter 12 of Abundance, Generosity, and the State: An Inquiry into Economic Principles audiobook.

From pp. 364–392 in the print edition.

Chapter 12. Interventionism and Side-Effect Goods

The Introduction to Abundance, Generosity, and the State: An Inquiry into Economic Principles audiobook.

From pp. 1–28 in the print edition.

Introduction

Part Two: Gratuitous Goods in a Free Economy

Chapter 8 of Abundance, Generosity, and the State: An Inquiry into Economic Principles audiobook.

From pp. 247–260 in the print edition.

Chapter 8. Natural Limits to Gratuitous Goods

Part Two: Gratuitous Goods in a Free Economy

Chapter 7 of Abundance, Generosity, and the State: An Inquiry into Economic Principles audiobook.

From pp. 219–246 in the print edition.

Chapter 7. The Equivalence Postulate

Part One: The Nature of Gratuitous Goods

Chapter 2 of Abundance, Generosity, and the State: An Inquiry into Economic Principles audiobook.

From pp. 63–94 in the print edition.

Chapter 2. The Nature of Donations

Economist Alex Tabarrok joins Bob to review Trump’s executive order on prescription drug pricing. They explore how price discrimination works in global pharmaceutical markets, the unintended consequences of importation policies, and why U.S. consumers often pay more—yet benefit most from drug innovation. Tabarrok also critiques the FDA’s role in delaying treatments and explains how regulatory reform, not price caps, could make healthcare more affordable and effective.

Alex's Article, "Econ 101 is Underrated: Pharma Price Controls": https://Mises.org/HAP500a

Why Are US Drug Prices So High?

Vincent Geloso and Chandler Reilly have a new paper in which they use Rothbard's "Private Product Remaining" (PPR) as a lower bound on estimates of national output, to be contrasted with the convention GDP statistics as an upper bound. Bob has the authors explain Rothbard's proposal and how they are trying to introduce it to the economics profession.

The Paper, "National Output Without Government?": https://Mises.org/HAP503a
The Human Action Podcast Episode on Dubious Origins of GDP/GNP: https://Mises.org/HAP503b
The Bob Murphy Show Episode With Alex Salter Criticizing "State Capacity": https://Mises.org/HAP503c

New Academic Paper Uses Rothbard's National Output Metric

Bob hosts economist Daniel Lacalle to analyze the controversial Big Beautiful Bill. Daniel explains why, despite its imperfections, the bill represents a vital first step toward curbing government spending and protecting private-sector prosperity from excessive state intervention.

Daniel's Article, "The Big Beautiful Bill Is Much Better Than You Think": https://Mises.org/HAP504a
Thomas Massie's X Exchange on the Hidden Costs of the BBB: https://Mises.org/HAP504b

The Debate Over the Big Beautiful Bill

The Mises Institute, founded in 1982, is an educational institution devoted to advancing Austrian economics, freedom, and peace in the classical-liberal tradition. Our website offers many thousands of free books and thousands of hours of audio and video, along with the full run of rare journals, biographies, and bibliographies of great economists.

New tracks tagged #mises